Gilead And Arcus’ Latest Update Keeps TIGIT Hopes Afloat

Data Readout On 20 December

 
• By Andrew McConaghie
  
Arcus Biosciences
Arcus and Gilead hope their 'Fc-silent' molecule will have a better safety and efficacy profile than other TIGITs. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip